There is a good chance that intermediate-risk breast cancer patients will not get chemotherapy in future, Gary Culliton reports in his latest Clinical Update. However, high-risk patients, who will benefit from chemotherapy, will get it.
Researchers at Queen’s University have made a significant breakthrough that may benefit patients with bowel cancer.
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals experimental research published online in the Journal of Clinical Pathology.
The development of the first alpha-emitting radionuclide is set to usher in a new era in prostate cancer treatment. Dawn O’Shea spoke to UCD graduate and Belfast oncologist Prof Joe O’Sullivan who was one of the lead investigators involved in developing the new ground-breaking therapy.
Photodynamic therapy (PDT), which uses topical agents and light to kill tissue, appears to better clear actinic keratoses (AKs), a common skin lesion caused by sun damage, at three months after treatment than cryotherapy
Three papers published in The Lancet Psychiatry, The Lancet, and The Lancet Oncology reveal that around three-quarters of cancer patients who have major depression are not currently receiving treatment for depression
A new study conducted by researchers from the RCSI shows that higher selenium levels are associated with decreased risk of bowel cancer, especially in women.
Invitation to modern mammography screening may reduce deaths from breast cancer by about 28 per cent, suggests a study from Norway published on bmj.com.
Patients in Ireland have been involved in a breakthrough international trial of a new cancer drug that has given researchers renewed hope in the fight against leukaemia.
This is an exciting time in the development of new agents for the management of advanced prostate cancer and the future looks bright, say Dr David Galvin and Dr Gerard McVey.